CD274 and non-small cell lung carcinoma: These results provide clinical information regarding the efficacy and safety of Niv+Ipi in PD-L1-positive advanced NSCLC, indicating the possibility of Niv+Ipi as a new therapeutic option as a first-line treatment for PD-L1-positive advanced NSCLC.